Abstract
Purpose::
The ANCHOR study was designed to investigate the efficacy and safety of monthly intravitreal ranibizumab compared to verteporfin PDT in predominantly classic lesions secondary to AMD over two years.
Methods::
In the ANCHOR trial, patients were randomized to receive monthly intravitreal ranibizumab 0.3mg plus sham PDT (n=140) or ranibizumab 0.5mg plus sham PDT (n=143), or verteporfin-PDT plus sham ranibizumab (n=140). Contrast sensitivity was assessed using Pelli-Robson charts, measuring the number of correctly identified letters.
Results::
At the Month-12 timepoint, monthly administration of both doses of ranibizumab increased contrast sensitivity over baseline by a mean of approximately 3 and 4 letters, respectively (both p<00001), in the ranibizumab 0.3mg and 0.5mg treatment groups. Contrast sensitivity in the verteporfin PDT group demonstrated a mean decrease of 3 letters at 12 months. Two year results from the ANCHOR study are currently under analysis and will be presented at this meeting.
Conclusions::
Interim 12 month results from the ANCHOR study demonstrate that ranibizumab 0.3mg and 0.5mg significantly improved contrast sensitivity in predominantly classic CNV lesion types when assessed using Pelli-Robson charts. Two-year data from ANCHOR will be presented.
Clinical Trial::
www.clinicaltrials.gov nct00061594
Keywords: age-related macular degeneration • contrast sensitivity • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials